At Farcast, we believe the way every tumor is tested and treated must reflect the highly unique nature of cancer. Treatment that drives strong response in one patient might not work in another, resulting in ineffective therapy that wastes critical time. Our platform tests a patient’s tumor to identify what will work before treatment begins. The result is individualized, actionable, and revolutionary.
Our mission is to reveal the most effective therapeutic response using tumor-specific results from a human system unlike any other. Farcast delivers practical insights that can help clinicians, researchers, and drug developers determine their most promising course of action sooner and more efficiently than ever before.
Our method of harvesting tumor fragments faithfully preserves native tumor architecture that can include tumor cells, stromal cells, and immune cells.
H&E staining of a representative breast cancer tumor fragment
(20X magnification)
This figure shows the relative impact of a drug, the current standard of care, and both combined.
Proliferative and apoptotic states are evaluated based on Ki-67 and active caspase-3 expression, respectively. Results represent the average from 3 randomized sections following a 72-hour culture period. Percentages refer to proportion of proliferating or apoptotic cells within the total number of tumor cells present within each fragment.
By focusing on the tumor cells with heterogeneous tumor fragments, Farcast shows the relative balance of living and dying tumor cells when exposed to various therapies.
